NIT do

INSTITUTO BUTANTAN

800.000 m21901Established to produce serum against the bubonic plague

Vital Brazil, first director, investigated antivenoms against snake

bites

INSTITUTO BUTANTAN

• 23 scientific labs

- Scientific Development Division [16 Labs]

- Biotechnology Center [3 labs]

- Applied Toxinology Special Lab – LETA [4 labs]

• Hospital Vital Brazil [10 beds]

• Central Animal Facility

• 180 PhD researchers

• 500 graduated students

• more than 200 published articles

• 4.274 citations in 2013

• Programs of Scientific Initiation

• Training Programs

• University Extension Courses

• Graduated studies in Toxinology

• MBA in Innovation

• Graduated inter-unities studies in Biotechnology [University

of São Paulo, Institute for Technological Research, Instituto Butantan]

Source: Instituto Butantan; ISI web of science

INSTITUTO BUTANTAN

7 plants

• Anaerobic vaccines

- Tetanus and Botulism

• Bacterial Purification Center

• Aerobic Vaccines

- Diphtheria and Pertussis

• Hepatitis

• Influenza

• Rabies

• Serums

1 Formulation and Filling Center

6 pilot plants

• Dengue

• Rotavirus

• Recombinant BCG

• Monoclonal antibodies

• Influenza - H5N1

• Blood products

PORTFOLIO OF SERUM

5 snake antivenoms Diphtheria

antitoxin

Spider antivenom

Caterpillar

antivenom

Tetanus antitoxin

Botulism E antitoxin

Rabies

immunoglobulin

Botulism AB

antitoxin

Scorpion

antivenom

13 immunoglobulins 400,000 vials/year

PORTFOLIO OF VACCINES

DTP Diphtheria-Tetanus-Pertussis

(celular)

DT

Diphtheria-Tetanus

(for children)

dT

Diphtheria-Tetanus

(for adults)

Rabies

Hepatitis B

Influenza

6 vaccines of the national calendar 150 million doses per year

PARTNERSHIPS

Harvar

d

TTO Instituto Butantan’s TTO was

established in 2012.

Classification Number

vaccine 12

serum 3

immunotherapy 3

coagulant 2

analgesic 2

peptide 2

tissue regeneration 2

anti cancer 1

antibodies 2

other* 11

total 40

Lopap – 4 patentsBiolab

Amblyomin-X – 1 patentUnião Química Ind. Farmacêutica

Sílica (SBA-15) – 1 patent

Cristália

Pertussis low – 1 patent

* other includes: proteins from Leptospira, spiderproteins, DNA of S. mansoni, crotamine, kit andcomposition, recombinant protein for diagnosis, etc.

SOME TECHNOLOGIES

TETRAVALENT VACCINE: DTP+PNEUMONIAE

• Priority application number: PI1003753-5;

• Priority data: 28 september 2010;

• Title: Synergistic immunogenic compositions based on protein antigenscombined with pertussis cell antigen and inactivated toxins;

• Geographical coverage: Brazil and United States of America;

• Abstract: Pneumococcal surface protein A (PSPA) is an antigen for thecomposition of protein-based vaccines against Streptococcus pneumoniae. Thesuccessfully addition of pneumococcal protein in to pertussis whole cell vaccinewas demonstrated. We propose a tetravalent vaccine DTP + PSPA. We aredeveloping pnemococcal antigens for the conjugation.

• More info: nit@butantan.gov.br

BCG RECOMBIANT VACCINE

• Priority application number: BR1020120037904;

• Priority data: 17 february 2012;

• Title: Recombinant mycobacterium bovis bacillus calmette guerin (BCG)strain, immunogenic composition and use;

• Geographical coverage: Brazil, United States of America, Europe,China, India and South Africa;

• Abstract: Production of a recombinant vaccine for prevention againsttuberculosis and infections caused by Mycobacterium. Results havedemonstrated that the protection is enhanced three times. We have alreadydone concept proofs.

• More info: nit@butantan.gov.br

ANTI-DIGOXIN MONOCLONAL ANTIBODY

• Priority application number: BR1020120114933;

• Priority data: 15 june 2012;

• Title: Method for producing and obtaining variable domains of anti-digoxinmonoclonal antibody FAB fragment using the molecular biology cloningtechnique;

• Geographical coverage: Brazil and PCT

• Abstract:Monoclonal antibody produced by phage display technology thatworks as an antidote and is used in the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose. Thisantibody is not produced in animals. It is in scaling up process of development.

• More info: nit@butantan.gov.br

THANK YOU!Luciana Akissue de C. Teixeira

Coordinator of Instituto Butantan’s TTO55 (11) 2627 9669

luciana.teixeira@butantan.gov.br